# NCT03589326 (NCT03589326)

> A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03589326
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Takeda
- Conditions: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
- Interventions: Ponatinib; Imatinib; Vincristine; Dexamethasone; Cytarabine; Methotrexate; Prednisone
- Enrollment: 245
- Primary outcome: Number of Participants With Minimal Residual Disease (MRD)-Negative Complete Remission (CR) at The End of Induction Phase

## Indexed commentary on NCT03589326 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03589326